Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson medTech — Research and development expense ($M) ($M)
Form 10-Q / 10-K Segment Note
Latest, Q3 2026
764
Period ended Sep 30, 2026
Change on a year earlier
+4.9%
728 in Q3 2025
History
12 quarters
Since Q3 2021
Sources
8
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | MedTech — Research and development expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 764 | +4.9% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 778 | +20.2% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 714 | +5.5% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 786 | -50.9% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 728 | -1.5% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 647 | -9.9% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 677 | +4.8% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 1,600 | – | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 739 | – | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 718 | – | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 646 | – | Form 10-Q (filed 2025-04-23) ↗ |
| Q3 2021 | Oct 3, 2021 | 900 | – | Form 10-Q (filed 2021-10-29) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson MedTech — Research and development expense ($M) ($M), quarterly Q3 2021–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_rd_mt
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.